2021
DOI: 10.1101/2021.02.23.432419
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Small-molecule inhibitors of the RNA m6A demethylase FTO potently support the survival of dopamine neurons

Abstract: The fat mass and obesity-associated protein (FTO), an RNA N6-methyladenosine (m6A) demethylase, is an important regulator of central nervous system development, neuronal signalling and disease. We present here the target-tailored development and biological characterization of small-molecule inhibitors of FTO. The active compounds were identified using high-throughput molecular docking and molecular dynamics screening of the ZINC compound library. In FTO binding and activity-inhibition assays the two best inhib… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 54 publications
(89 reference statements)
0
1
0
Order By: Relevance
“…Currently, several therapeutic strategies have been proposed involving m 6 A demethylase inhibitors for various diseases, including glioblastoma and neurodegenerative conditions (Selberg et al, 2021;Huff et al, 2022;You et al, 2022). However, due to the diverse effects of m 6 A modification on RNA metabolism, generally manipulating m 6 A levels could result in potential side effects.…”
Section: Interfering With Epitranscriptomic Pathways For Therapeutic ...mentioning
confidence: 99%
“…Currently, several therapeutic strategies have been proposed involving m 6 A demethylase inhibitors for various diseases, including glioblastoma and neurodegenerative conditions (Selberg et al, 2021;Huff et al, 2022;You et al, 2022). However, due to the diverse effects of m 6 A modification on RNA metabolism, generally manipulating m 6 A levels could result in potential side effects.…”
Section: Interfering With Epitranscriptomic Pathways For Therapeutic ...mentioning
confidence: 99%